Potent Cholesteryl Ester Transfer Protein Inhibitors of Reduced Lipophilicity: 1,1′-Spiro-Substituted Hexahydrofuroquinoline Derivatives

Thomas Trieselmann(Boehringer Ingelheim (Germany)), Herbert Nar(Boehringer Ingelheim (Germany)), Dieter Hamprecht, Klaus Fuchs(Boehringer Ingelheim (Germany)), Daniela Berta, Astrid Volz(Boehringer Ingelheim (Germany)), Paolo Cremonesi, Rüdiger Streicher(Boehringer Ingelheim (Germany)), Gerd Luippold(Boehringer Ingelheim (Germany)), Holger Wagner(Boehringer Ingelheim (Germany)), Michael Markert(Boehringer Ingelheim (Germany))
Journal of Medicinal Chemistry
September 29, 2014
10.1021/jm500431d
Cited by 27

Related Papers

A specific antidote for dabigatran: functional and structural characterization
|Blood|2013|562
Crystal structure analysis of oxidized Pseudomonas aeruginosa azurin at pH 5·5 and pH 9·0
|Journal of Molecular Biology|1991|487
Structure-Based Design of Novel Potent Nonpeptide Thrombin Inhibitors
|Journal of Medicinal Chemistry|2002|454
Biophysics in drug discovery: impact, challenges and opportunities
|Nature Reviews Drug Discovery|2016|383
8-(3-(<i>R</i>)-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a Highly Potent, Selective, Long-Acting, and Orally Bioavailable DPP-4 Inhibitor for the Treatment of Type 2 Diabetes
|Journal of Medicinal Chemistry|2007|285